Best of ASCO Slovakia

Transcription

1 Slovenská onkologická spoločnosť Vás pozýva na akreditované podujatie Americkej spoločnosti klinickej onkológie Slovak Oncology Society invites you to attend the licensed conference of American Society of Clinical Oncology Best of ASCO Slovakia 3. október 2009/3 rd October 2009 Holiday Inn, Bratislava Výber toho najlepšieho z kongresu ASCO prezentované lídrami slovenskej i svetovej onkológie The cutting edge results from ASCO Annual meeting presented by the leaders of Slovak and world oncology

2 Best of ASCO Slovakia / 3. október 2009/3 rd October 2009, Holiday Inn, Bratislava z na / from October 2 nd to October 3 rd 2009: áno / Yes nie / No z na / from October 3 rd to October 4 th 2009: áno / Yes nie / No Pri prihlásení do ubytovanie zabezpečí organizátor. / The organizer will provide the accomodation if applied no later than 31st of August Pri prihlásení po je potrebné uhradiť registračný poplatok 30,- EUR. / If registred after 31st of August, the registration fee of 30,- EUR applies. V prípade záujmu o účasť vyplnenú prihlášku zašlite poštou, faxom, om na adresu Completed applications of attendance may be sent by mail, fax or to the following address: POKO Poprad, s. r. o., Mnoheľova 2, Poprad fax: (0) , pokopopradsro@mail.t-com.sk najneskôr do / no later than 31 st of August PRIHLÁŠKA Meno, priezvisko, titul / First name, surname, title: Adresa pracoviska / Work address: Tel: Fax: Reg. č. Slovenskej lekárskej komory / No. of Slovak Medical Chamber: Ubytovanie / Accomodation:

3 ODBORNÝ PROGRAM Registration Welcome Chairmen of the breast cancer session Ivan Koza, Igor Andrašina ( ) Adjuvant and neoadjuvant breast cancer (Igor Andrašina) 1. Thjan-Heijnen, V. Impact of omission of completion axillary lymph node dissection (calnd) or axillary radiotherapy (axrt) in breast cancer patients with micrometastases (pn1mi) or isolated tumor cells (pn0(i+)) in the sentinel lymph node (SN): results from the MIRROR study. 2. Watanabe, T. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node positive breast cancer Results of N-SAS-BC02 trial. 3. Gonzales-Angulo, A. Adjuvant radiation therapy benefits breast cancer patients with 1 to 3 positive lymph nodes undergoing a modified radical mastectomy and systemic therapy. 4. Esserman, L. Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY trial (CALGB /150012, ACRIN 6657) Metastatic breast cancer (Tanja Čufer) 1. Seidman, A. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). 2. Robert, N. RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for 1st line treatment of HER2-negative locally-recurrent or metastatic breast cancer (MBC). 3. Vogel, C. A phase II study of trastuzumab-dm1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. 4. O Shaugnessy, J. Efficacy of BSI-201, a Poly (ADP-ribose) Polymerase-1 (PARP1) inhibitor, in Combination With Gemcitabine/Carboplatin (G/C) in Patients with Metastatic Triple Negative Breast Cancer (TNBC): Results of a Randomized Phase 2 Trial. 5. Tutt, A. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer Discussion 1st Announcement Programme Best of ASCO in Slovakia Official languages: Slovak, English Chairmen of the lung cancer session Peter Kasan, Peter Beržinec ( ) Lung cancer (Thomas Brodowicz) 1. Felip, E. Surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage-non-small cell lung cancer (NSCLC): Results of NATCH multicenter, randomized, phase III trial. 2. Fouret, P. MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer. 3. Chlebowski., R. Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the women s health initiative randomized clinical trial. 4. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st line platinum-based chemotherapy in patients with advanced NSCLC. 5. Miller, V. A randomized, double blind, placebo controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of

4 Discussion chemotherapy with B for 1st line treatment of locally-advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). 6. Belani, C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). 7. O Byrne, K. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. Chairmen of the hematologic malignancies session Andrej Vranovský, Jan Hudeček, ( ) Hematologic malignancies lymphoma, leukemia (Stanislav Špánik) 1. Schuster, S. Idiotype vaccine therapy (BiovaxIDTM) in follicular lymphoma in first complete remission: phase III clinical trial results. 2. Cunningham, D. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B cell non-hodgkin s lymphoma. 3. Gisselbrecht, C. R-ICE versus D-HAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. 4. Fernandez, H. A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E Palumbo, A. A Phase III Study of VMPT versus VMP in newly diagnosed elderly myeloma patients Discussion Lunch ODBORNÝ PROGRAM Chairmen of the urogenital and gynecologic cancer Tibor Packáň, Jozef Mardiak ( ) Urogenital malignancies (Jozef Mardiak) 1. Rini, B. Bevacizumab plus interferon-alpha versus interferon-alpha Mnonotherapy in Patients wit Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB Escudier, B. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mrcc). 3. Sternberg C. A randomized, double-blind phase III study of Pazopanib in treatmentnaïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). 4. Scher, H. Antitumor activity of MDV3100 in a Phase 1-2 study of Castration- Resistant Prostate Cancer (CRPC) Gynecologic malignancies (Jan B. Vermorken) 1. Pignata, S. Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): final results of the MITO-2 randomized multicenter trial. 2. Pujade-Lauraine, E. CALYPSO phase III study: comparison of carboplatin (C) pegylated liposomal doxorubicin (PLD) (C-D) and carboplatin-paclitaxel (C-P) in relapsed platinumsensitive ovarian cancer (OC) by the Gynecologic Cancer Intergroup (GCIG). 3. Herrstedt, J. A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO- OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. 4. Rustin, G. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC trials) Discussion

5 ODBORNÝ PROGRAM Chairmen of the gastrointestinal cancer and varia session Pavol Dubinský, Vladimír Malec ( ) Gastrointestinal colorectal cancer (Tomáš Šálek) 1. Gerard, JP. Randomized multicenter phase III trial comparing two neoadjuvant chemo-radiotherapy (CT-RT) regimens (RT45-Cap vs RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC). Results of the ACCORD 12/0405 PRODIGE Wolmark, N. A phase III trial comparing mfolfox6 to mfolfox 6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C Tejpar, S. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5-FU-LV and irinotecan (PETAC 3 EORTC SAKK 60/00 trial). 4. Aschele, C. Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the STAR (Studio Terapia Adiuvante Retto)-01 randomized phase III trial Gastrointestinal noncolorectal cancer (Mária Wágnerová) 1.Van Cutsem, E. Efficacy results from ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) 2. Schuhmacher, C. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC Phase III Trial # James, R. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/fu in squamous cell carcinoma of the anus (ACT II). 4. Valle, J. Gemcitabine with or without cisplatin in patiens (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomized phase III trial (the UK ABC-02 trial). 5. Neoptolemos, J. ESPAC-3(v2) A multicentre, international, open label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. 6. Arnold, R. Placebo-controlled, double-blind, prospective, randomized study of the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group Varia head and neck, public health, survivorship (Juraj Beniak) 1. Hitt, R. Final results of a randomized phase III trial comparing induction chemotherapy withs cisplatin/5-fu (PF) or docetaxel/cisplatin/5-fu (TPF) followed by chemoradiotherapy (CRT) versus CRT alone as first line treatment of unresectable locally advanced head and neck cancer (LAHNC). 2. Gillison, M. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG Mueller, R. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastatses results of the EORTC study. 4. Nathan, P. Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). 5. Ryan, J. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. 6. Jean-Pierre P. Neuroprotective effects of SSRI among 781 cancer patients receiving chemotherapy: A URCC CCOP Study Discussion Farewell

6 Termín / Date: 3. október 2009/3 rd October 2009 Miesto / Place: Holiday Inn, Bajkalská 25/A, Bratislava Organizátor / Organizer: POKO Poprad, s. r. o., Slovenská onkologická spoločnosť Slovenskej lekárskej spoločnosti Organizačný výbor / Organizing Committee: doc. MUDr. Igor Andrašina, CSc., VOÚ, Košice, Slovakia prim. MUDr. Juraj Beniak, POKO Poprad, Slovakia MUDr. Marián Kakalejčík, POKO Poprad, Slovakia prof. MUDr. Ivan Koza, DrSc., NOÚ, Bratislava, Slovakia doc. Jozef Mardiak, CSc. NOÚ, Bratislava, Slovakia MUDr. Mária Rečková, POKO Poprad, Slovakia prof. MUDr. Stanislav Špánik, CSc., OÚSA, Bratislava, Slovakia Prednášajúci, predsedajúci / Faculty: doc. MUDr. Igor Andrašina, CSc., VOÚ, Košice, Slovakia MUDr. Juraj Beniak, POKO Poprad, Slovakia doc. MUDr. Peter Beržinec, CSc., OÚTaRCH, Nitra, Slovakia Univ. Prof. Thomas Brodowicz, MD, Medical University, Vienna, Austria Prof. Tanja Čufer, MD, PhD., University Clinic, Golnik, Slovenia prim. MUDr. Pavol Dubinský, PhD, VOÚ, Košice, Slovakia doc. MUDr. Jan Hudeček, CSc., KHT MFN, Martin, Slovakia doc. MUDr. Peter Kasan, CSc., NÚTaRCH, Bratislava, Slovakia prof. MUDr. Ivan Koza, DrSc., NOÚ, Bratislava, Slovakia prim. MUDr. Vladimír Malec, PhD., FNsP, Banská Bystrica, Slovakia doc. MUDr. Jozef Mardiak, CSc., NOÚ, Bratislava, Slovakia prim. MUDr. Tibor Packáň, VOÚ, Košice, Slovakia prim. MUDr. Tomáš Šálek, NOÚ, Bratislava, Slovakia prof. MUDr. Stanislav Špánik, CSc., OÚSA, Bratislava, Slovakia Prof. Jan B. Vermorken, MD, PhD., Antwerp University Hospital, Belgium MUDr. Andrej Vranovský, NOÚ, Bratislava, Slovakia doc. MUDr. Mária Wágnerová, CSc., VOÚ, Košice, Slovakia Mediálny partner / Media partner: SOLEN, s. r. o. Oficiálny kongresový jazyk / official conference language: slovenčina, angličtina / Slovak, English. Podujatie bude ohodnotené CME kreditmi. / The attendees will receive CME credits. VŠEOBECNÉ INFORMÁCIE